ISSN:
1569-8041
Keywords:
ALL
;
childhood
;
L-asparaginase
;
L-asparagine
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Purpose:The present study was aimed at investigatingL-asparaginase (L-ASE) activity (in plasma) and L-asparagine (L-ASN) depletion(in plasma and CSF) in children with newly diagnosed acute lymphoblasticleukemia (ALL) exposed for the first time to different L-ASE products. Patients and methods:During the induction treatment of the AIEOPALL 95 study, 62 patients were treated with either Erwinase® (n=15), or E. colimedac® (n= 47) L-ASE products, giveneither i.m. or i.v., at the standard dosage of 10,000 IU/m2, q 3days × 8 (first exposure). Results:Plasma and CSF L-ASN trough levels were undetectable inall cases, including those with L-ASE trough activity 〈50 mU/ml. L-ASEtrough activity during the administration of medac® was howeversignificantly higher when compared with that of Erwinase®. Conclusions:L-ASN depletion after a first exposure to standarddoses of Erwinase® or medac® is obtained in virtually all patients.No differences are seen between the I.M. or I.V. administration routes but themedac® product is associated with a significantly higher enzyme activityin respect of Erwinase®. L-ASN levels may be undetectable also in patientswith L-ASE trough activity levels 〈50 mU/ml, challenging the currentopinion that an activity level of 100 mU/ml is needed to obtain L-ASNdepletion.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1023/A:1008368916800
Permalink